5/19/2010

FibroGen reported that its human monoclonal antibody caused regression of tissue scarring in mice with radiation-induced idiopathic pulmonary fibrosis. The experimental drug, FG-3019, is undergoing clinical trials for diseases including diabetes and advanced liver fibrosis.

Related Summaries